SS-31: Mitochondria-Targeted Peptide Research

Palmetto Peptides Research Team

February 22, 2026

anti-agingmitochondriapeptidesresearchss-31

SS-31 (also known as Szeto-Schiller peptide 31 or D-Arg-Dmt-Lys-Phe-NH2) is a cell-permeable, mitochondria-targeted tetrapeptide developed by Hazel H. Szeto and Peter W. Schiller. Unlike conventional antioxidants that must be consumed in large quantities to achieve intracellular effects, SS-31 is selectively concentrated in the inner mitochondrial membrane at levels several hundredfold greater than cytoplasmic concentrations, where it interacts directly with cardiolipin — a phospholipid critical to mitochondrial function and electron transport chain integrity.

Structure and Mitochondrial Targeting

SS-31's four-residue sequence alternates basic and aromatic residues: D-Arg (D-arginine), Dmt (2',6'-dimethyltyrosine), Lys (lysine), and Phe-NH2 (phenylalanine amide). This alternating aromatic-cationic motif is shared across the SS peptide family and is responsible for two key properties:

Mitochondrial targeting: The overall positive charge at physiological pH drives electrophoretic accumulation across the large negative mitochondrial membrane potential (Δψm = -180 mV), concentrating SS-31 approximately 1,000-fold in the mitochondrial matrix and inner membrane.
Cardiolipin interaction: The aromatic residues interact with cardiolipin head groups via hydrophobic and electrostatic interactions, stabilizing cardiolipin's structural role in respiratory chain supercomplexes.

Mechanism of Action: Cardiolipin Interaction

Cardiolipin is a unique dimeric phospholipid found almost exclusively in the inner mitochondrial membrane. It plays essential roles in organizing the respiratory chain supercomplexes (I-III-IV), maintaining membrane curvature at cristae junctions, and facilitating cytochrome c electron transfer. During cellular stress and aging, cardiolipin is progressively oxidized by reactive oxygen species (ROS), leading to cytochrome c release from the inner membrane and impaired electron transport chain function.

Electron Transport Chain Preservation

SS-31 research has demonstrated that the compound directly interacts with cardiolipin via the dimethyltyrosine residue, inhibiting cardiolipin peroxidation. By preserving cardiolipin's structural integrity, SS-31 maintains cytochrome c binding to the inner membrane, sustaining efficient electron transport and reducing electron leak that would otherwise generate superoxide radicals. This cardiolipin-protective mechanism represents a fundamentally different approach to mitochondrial research compared to conventional radical-scavenging antioxidants.

ATP Production Research

Multiple in vitro and in vivo studies have documented that SS-31 improves mitochondrial ATP production rates in models of mitochondrial dysfunction. Research using aged cardiomyocytes demonstrated SS-31-mediated restoration of state III respiration rates and increased ATP/ADP ratios, directly linking cardiolipin preservation to improved bioenergetic function.

Key Research Findings

Aging and Age-Related Dysfunction

Research by Siegel et al. and others established that mitochondrial dysfunction driven by cardiolipin oxidation is a central mechanism in age-related tissue degeneration. SS-31 studies in aged rodent models have consistently demonstrated improvements in cardiac function, skeletal muscle performance, and neurological measures, providing a research framework for understanding how mitochondrial protection translates to systemic functional outcomes. Research in aged mice showed SS-31-treated animals had significantly improved treadmill performance and reduced markers of oxidative stress compared to controls.

Ischemia-Reperfusion Injury

Among the most replicated findings in SS-31 research is protection against ischemia-reperfusion (I/R) injury in cardiac and renal models. I/R injury involves a paradoxical burst of ROS production when blood flow is restored to ischemic tissue, causing mitochondrial damage. Multiple independent research groups have reported that SS-31 pretreatment significantly reduces infarct size in cardiac I/R models, with some studies reporting >50% reduction in infarct volume. These findings have positioned SS-31 as a reference compound in mitochondrial cardioprotection research.

Kidney Research

SS-31 (also known as Bendavia or MTP-131 in clinical research contexts) has been studied in models of acute kidney injury (AKI). Research demonstrated that SS-31 administration preserved renal tubular function and reduced markers of oxidative damage in cisplatin-induced nephrotoxicity and I/R-induced AKI models in rodents.

Neurodegenerative Research

Mitochondrial dysfunction is increasingly recognized as a pathological driver in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. Research using SS-31 in transgenic AD mouse models has reported reduced amyloid plaque burden, improved synaptic function, and better performance on cognitive tasks — findings attributed to preserved mitochondrial function in neurons.

Research Protocols

SS-31 is typically supplied as a lyophilized white powder for reconstitution. In animal research, it is commonly administered subcutaneously or intravenously. The compound's short plasma half-life (~2 hours) means that dosing protocols in animal studies typically involve daily administration or osmotic pump delivery for sustained exposure. Storage requires refrigeration and protection from light; the Dmt residue and the amide C-terminus are susceptible to degradation under alkaline conditions.

SS-31 and MOTS-c: Complementary Mitochondrial Research Tools

MOTS-c is a 16-amino acid peptide encoded in the mitochondrial 12S rRNA gene that regulates metabolic homeostasis and stress resistance. While SS-31 directly protects cardiolipin and the electron transport chain, MOTS-c primarily functions as a metabolic hormone, translocating to the nucleus and regulating stress-responsive gene expression. Together they represent complementary tools for studying different facets of mitochondrial biology.

Frequently Asked Questions

How is SS-31 different from CoQ10 and other mitochondria-targeted antioxidants?

CoQ10 and MitoQ function primarily by scavenging electrons and ROS. SS-31's primary mechanism is structural — it stabilizes cardiolipin and thereby preserves the organization of the electron transport chain, preventing ROS generation at the source rather than quenching it after formation. This represents a mechanistically distinct and potentially more efficient approach to mitochondrial protection.

What clinical development has SS-31 undergone?

SS-31 (as Elamipretide/Bendavia/MTP-131) has been studied in Phase I/II clinical trials for heart failure with preserved ejection fraction (HFpEF), Barth syndrome, and primary mitochondrial myopathy. While full regulatory approval has not been obtained, these trials have established human safety profiles and provided pharmacokinetic data valuable to researchers.

Why is cardiolipin so important to mitochondrial function?

Cardiolipin's unique dimeric structure and location at the inner mitochondrial membrane make it critical for cytochrome c binding, cristae structure, respiratory chain supercomplex formation, and mitochondrial membrane potential maintenance. Its oxidation during stress is an early and amplifying event in mitochondrial dysfunction — explaining why cardiolipin protection is a powerful leverage point for mitochondrial research.

References

Szeto HH, et al. (2004). Mitochondria-targeted electron scavengers. AAPS Journal. PMID: 15760069
Birk AV, et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. PMID: 23687360
Siegel MP, et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. PMID: 23590178

Disclaimer: All compounds offered by Palmetto Peptides are strictly for laboratory research and in vitro studies. They are not intended for human consumption, veterinary use, or any therapeutic application. All information provided is for educational and scientific reference only. Palmetto Peptides makes no health claims. Consult a licensed medical professional before handling any research compound.